No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
Ready to participate?
Review the details below, then apply to join this clinical trial.
At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
447 (estimated)
Sponsor
University Hospital, Lille · Other
Who this trial is looking for
This trial is looking for people with alcoholic liver disease, including those with severe alcoholic hepatitis. Participants will help researchers understand how common these conditions are and how to assess their severity.
Are You a Good Fit for This Trial?
You may be able to join if
I drink more than 40 grams of alcohol a day if I am a woman, or more than 50 grams if I am a man.
I have consumed alcohol for more than 5 years.
I have had jaundice in the last 3 months.
My bilirubin level is more than 50 mg/l.
You may not be able to join if
I have another liver disease.
I have liver cancer.
I am HIV positive.
Summarized in plain language from this trial's official eligibility criteria.
The full criteria are further down this page — only the research team can
confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Alcoholic hepatitis carries a risk of high mortality at short term, especially in its severe form. Its diagnosis is confirmed by liver biopsy. The prevalence of alcoholic hepatitis, severe or not severe, is poorly known and prospective data are needed. The present observational study aims to define the prevalence of alcoholic hepatitis among patients admitted for jaundice and determine their outco…
Alcoholic hepatitis carries a risk of high mortality at short term, especially in its severe form. Its diagnosis is confirmed by liver biopsy. The prevalence of alcoholic hepatitis, severe or not severe, is poorly known and prospective data are needed. The present observational study aims to define the prevalence of alcoholic hepatitis among patients admitted for jaundice and determine their outcome according to the severity. Survival and markers of liver dysfunction will be assessed. A biobank including genetic samples will be created to identify the disease profile in terms of inflammation and regeneration. The performance of non-invasive criteria for diagnosis will also be studied.
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Inclusion Criteria:
For SAH group:
* Alcohol consumption :
* On average\> 40 g / day for women and 50 g / day for men
* Duration:\> 5 years
* Recent jaundice episode (less than 3 months)
* Bilirubin\> 50 mg / l (85μmol / l)
For NSAH group:
\- Alcohol consumption :
* On average\> 40 g / day…
Inclusion Criteria:
For SAH group:
* Alcohol consumption :
* On average\> 40 g / day for women and 50 g / day for men
* Duration:\> 5 years
* Recent jaundice episode (less than 3 months)
* Bilirubin\> 50 mg / l (85μmol / l)
For NSAH group:
\- Alcohol consumption :
* On average\> 40 g / day for women and 50 g / day for men
* Duration:\> 5 years
For cirrhosis (control) group:
* Alcohol consumption :
* On average\> 40 g / day for women and 50 g / day for men
* Duration:\> 5 years
* Unambiguous presence of cirrhosis criteria, including:
* clinical signs (ascites, stellar angiomas ...) and / or
* radiological signs (scanner or MRI: signs of hepatic dysmorphism and / or portal hypertension) and / or
* biological signs (increased INR, thrombocytopenia) and / or
* endoscopic signs (oesophageal / gastric varices)
Exclusion Criteria:
For NAH and NSAH groups:
* Presence of another hepatic pathology: evidenced by blood biology, imaging or histology (viral or autoimmune hepatitis, hemochromatosis, Wilson's disease)
* Presence of hepatocellular carcinoma
* HIV infection
For cirrhosis (control) group:
* History established / suggestive of HAA (Clinical, biological and / or histological criteria) in particular absence of jaundice episode
* Presence of another hepatic pathology: evidenced by blood biology, imaging or histology (viral or autoimmune hepatitis, hemochromatosis, Wilson's disease)
* Presence of hepatocellular carcinoma
* HIV infection
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.